Jump to content

Recommended Posts

Paul Edwards

With increasing options to treat advanced prostate cancer, there is no clear agreement on the order in which these treatments should be given.

 

I attach a chart prepared (following the STAMPEDE clinical trial which recommended early ADT and chemotherapy for certain patients) by an American oncologist setting out his view of what is currently best clinical practice in America.

 

post-93-0-84661400-1448591916_thumb.jpg

 

In Australia our options are more restricted: Abiraterone and Enzalutamide are only available on the Pharmaceutical Benefits Scheme after chemotherapy and Provenge is not available on the Pharmaceutical Benefits Scheme.

 

Oldtimer's Disease - I can't remember which publication I found this table in.  A prize for anyone who can tell me where it came from.

 

  • Like 1

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×